Co-targeting SOS1 enhances the antitumor effects of KRAS ^G12C inhibitors by addressing intrinsic and acquired resistance.

Autor: Thatikonda V; Boehringer Ingelheim RCV, Vienna, Austria. vthatikonda@exscientia.co.uk.; Exscientia, Vienna, Austria. vthatikonda@exscientia.co.uk., Lyu H; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jurado S; Boehringer Ingelheim RCV, Vienna, Austria., Kostyrko K; Boehringer Ingelheim RCV, Vienna, Austria., Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albrecht C; Boehringer Ingelheim RCV, Vienna, Austria., Alpar D; Boehringer Ingelheim RCV, Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV, Vienna, Austria., Bergner O; Boehringer Ingelheim RCV, Vienna, Austria., Bosch K; Boehringer Ingelheim RCV, Vienna, Austria., Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gerlach D; Boehringer Ingelheim RCV, Vienna, Austria., Gmachl M; Boehringer Ingelheim RCV, Vienna, Austria., Hinkel M; Boehringer Ingelheim RCV, Vienna, Austria., Lieb S; Boehringer Ingelheim RCV, Vienna, Austria., Jeschko A; Boehringer Ingelheim RCV, Vienna, Austria., Machado AA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Madensky T; Boehringer Ingelheim RCV, Vienna, Austria., Marszalek ED; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melo-Zainzinger G; Boehringer Ingelheim RCV, Vienna, Austria., Molkentine JM; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaeger PA; Boehringer Ingelheim RCV, Vienna, Austria., Peng DH; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schenk RL; Boehringer Ingelheim RCV, Vienna, Austria., Sorokin A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strauss S; Boehringer Ingelheim RCV, Vienna, Austria., Trapani F; Boehringer Ingelheim RCV, Vienna, Austria., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vellano CP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petronczki M; Boehringer Ingelheim RCV, Vienna, Austria., Kraut N; Boehringer Ingelheim RCV, Vienna, Austria., Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pearson M; Boehringer Ingelheim RCV, Vienna, Austria., Waizenegger IC; Boehringer Ingelheim RCV, Vienna, Austria., Hofmann MH; Boehringer Ingelheim RCV, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com.

Publikováno v: Nature cancer [Nat Cancer] 2024 Sep; Vol. 5 (9), pp. 1352-1370. Date of Electronic Publication: 2024 Aug 05.

Combined KRAS ^G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS ^G12C -driven cancers by addressing intrinsic and acquired resistance.

Autor: Thatikonda V; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Lu H; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jurado S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Kostyrko K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bosch K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gerlach D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Gmachl M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Lieb S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Jeschko A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Machado AA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek ED; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaeger PA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Sorokin A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strauss S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Trapani F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vellano CP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petronczki M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pearson M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Waizenegger I; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Jan 23. Date of Electronic Publication: 2023 Jan 23.

The Dfm1 Derlin Is Required for ERAD Retrotranslocation of Integral Membrane Proteins.

Autor: Neal S, Jaeger PA, Duttke SH, Benner C, Glass CK, Ideker T, Hampton RY

Publikováno v: Molecular cell [Mol Cell] 2018 Mar 01; Vol. 69 (5), pp. 915.

Erratum to: Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain.

Autor: Jaeger PA; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. pjaeger@ucsd.edu.; Institute of Chemistry and Biochemistry, Free University, Berlin, Berlin, Germany. pjaeger@ucsd.edu.; Departments of Bioengineering and Medicine, University of California, La Jolla, San Diego, CA, USA. pjaeger@ucsd.edu., Lucin KM; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.; Present address: Biology Department, Eastern Connecticut State University, Willimantic, CT, USA., Britschgi M; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.; Present address: Roche Pharma Research and Early Development, NORD DTA, Roche Innovation, Center Basel, Basel, Switzerland., Vardarajan B; Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine, Boston, MA, USA., Huang RP; RayBiotech, Guangzhou, China.; RayBiotech, Norcrosse, GA, USA., Kirby ED; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Abbey R; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Boeve BF; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Boxer AL; Department of Neurology, University of California San Francisco, San Francisco, CA, USA., Farrer LA; Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine, Boston, MA, USA.; Departments of Neurology, Ophthalmology, Genetics and Genomics, Epidemiology, and Biostatistics, Boston University Schools of Medicine and Public Health, Boston, MA, USA., Finch N; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA., Graff-Radford NR; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA., Head E; Departments of Pharmacology and Nutritional Sciences and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA., Hofree M; Department of Computer Science and Engineering, University of California, La Jolla, San Diego, CA, USA., Huang R; RayBiotech, Guangzhou, China.; RayBiotech, Norcrosse, GA, USA., Johns H; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Karydas A; Department of Neurology, University of California San Francisco, San Francisco, CA, USA., Knopman DS; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Loboda A; Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, PA, USA., Masliah E; Department of Pathology, University of California, La Jolla, San Diego, CA, USA., Narasimhan R; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Petersen RC; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Podtelezhnikov A; Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, PA, USA., Pradhan S; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Rademakers R; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA., Sun CH; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA., Younkin SG; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA., Miller BL; Department of Neurology, University of California San Francisco, San Francisco, CA, USA., Ideker T; Departments of Bioengineering and Medicine, University of California, La Jolla, San Diego, CA, USA., Wyss-Coray T; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.; Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System, Palo Alto, CA, USA. twc@stanford.edu.

Publikováno v: Molecular neurodegeneration [Mol Neurodegener] 2016 May 23; Vol. 11 (1), pp. 42. Date of Electronic Publication: 2016 May 23.

Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA.

Autor: Gross AM; Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093, USA; Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Jaeger PA; Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Kreisberg JF; Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Licon K; Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Jepsen KL; Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Khosroheidari M; Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Morsey BM; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA., Swindells S; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA., Shen H; Van Andel Research Institute, Grand Rapids, MI 49503, USA., Ng CT; aTyr Pharmaceuticals, San Diego, CA 92121, USA., Flagg K; Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Department of Ophthalmology and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Guangzhou Kang Rui Biological Pharmaceutical Technology Company Ltd., Guangzhou 510005, China., Chen D; Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Department of Ophthalmology and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Zhang K; Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Department of Ophthalmology and Biomaterials and Tissue Engineering Center, Institute for Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Veterans Administration Healthcare System, San Diego, CA 92093, USA; Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA., Fox HS; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: hfox@unmc.edu., Ideker T; Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093, USA; Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: tideker@ucsd.edu.

Publikováno v: Molecular cell [Mol Cell] 2016 Apr 21; Vol. 62 (2), pp. 157-168.